Exousia Bio (LMMY) EBITDA Margin (2023 - 2024)

Exousia Bio's (LMMY) quarterly EBITDA Margin came in at 17.76% in Q3 2024, down 106.14% quarter-over-quarter from 289.04% in Q2 2024.

Exousia Bio (LMMY) EBITDA Margin (2023 - 2024) Analysis & Trends

Exousia Bio has disclosed EBITDA Margin across 2 years of filings, most recently posting 17.76% for Q3 2024.

EBITDA Margin for Q3 2024 came in at 17.76%, changed N/A year-over-year; the trailing twelve-month figure through May 2025 was 113.81% (up 5926.0% YoY), and the FY2025 annual result was 465.73%, down 31386.0% from the prior year.
EBITDA Margin came in at 17.76% for Q3 2024 at Exousia Bio, down from 289.04% in the prior quarter.
In the past five years, EBITDA Margin ranged from a high of 289.04% in Q2 2024 to a low of 224.39% in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	51Talk Online Education	7.03 Bn	6.99 Bn	22.18 Mn	-16.93%
2	Laureate Education	5.22 Bn	5.06 Bn	-16.39 Mn	-10.10%
3	Graham Holdings	5.09 Bn	4.08 Bn	841.00 Mn	6.17%
4	Covista	4.40 Bn	4.40 Bn	276.31 Mn	18.75%
5	Stride	4.17 Bn	3.36 Bn	231.57 Mn	20.49%
6	Grand Canyon Education	3.94 Bn	3.69 Bn	244.77 Mn	30.92%
7	McGraw Hill	2.19 Bn	1.94 Bn	388.89 Mn	-9.39%
8	Universal Technical Institute	2.14 Bn	1.97 Bn	103.97 Mn	0.15%
9	Perdoceo Education	2.13 Bn	1.45 Bn	174.68 Mn	28.47%
10	Exousia Bio	-	-	-62,108.00	-

Download Data